Back grey_arrow_rt.gif
 
 
Doug Mayers Leaves Boehringer Ingelheim & Joins Idenix
 
 
  Press Release Source: Idenix Pharmaceuticals, Inc.
 
Idenix Pharmaceuticals, Inc. Announces Appointment of Douglas Mayers, M.D. as Executive Vice President and Chief Medical Officer
 
Monday January 8, 5:00 pm ET
 
CAMBRIDGE, Mass., Jan. 8 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX - News) today announced the appointment of Douglas Mayers, M.D. to the position of executive vice president and chief medical officer. Reporting to Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix, Dr. Mayers will be responsible for the company's clinical development activities. Dr. Mayers will replace Nathaniel Brown, M.D., who is resigning as an executive officer, but remaining affiliated with Idenix as a Senior Medical Advisor. The transition of the role of chief medical officer will occur at the end of January.
 
"Dr. Mayers' nearly 20 years of medical and clinical development experience in infectious diseases will be important as we seek to advance our hepatitis C and HIV clinical programs and to expand our pipeline with additional clinical drug candidates," said Dr. Sommadossi. "We are delighted to have Dr. Mayers join the senior management team of Idenix."
 
Dr. Sommadossi added, "I want to thank Dr. Brown for his valuable contributions to Idenix. Under his leadership, we successfully developed telbivudine for the treatment of hepatitis B from phase I through FDA approval in just six years and significantly advanced our hepatitis C clinical program. We look forward to continuing our working relationship with Dr. Brown."
 
Prior to joining Idenix, Dr. Mayers was International Head/Vice President, Therapeutic Area of Virology with Boehringer Ingelheim for five years and was responsible for the strategic coordination of all HIV and hepatitis clinical trials in phases I through IV. Prior to joining industry, Dr. Mayers conducted clinical trials in HIV research during his seventeen years in the Navy and his subsequent three years as the Head of Infectious Diseases with Henry Ford Hospital. Board certified in internal medicine and infectious diseases, Dr. Mayers completed his M.D. at the University of Pennsylvania. Dr. Mayers remains in the Navy Reserves and currently holds the rank of Captain.
 
About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and HIV. For further information about Idenix, please refer to http://www.idenix.com.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org